CASI Pharmaceuticals Inc – Strategy, SWOT and Corporate Finance Report

CASI Pharmaceuticals Inc – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company.

CASI Pharmaceuticals Inc (CASI) is a biopharmaceutical company, which focuses on the acquisition, development and commercialization of innovative therapies for treating cancer and other unmet medical needs. Its pipeline product portfolio includes ENMD-2076 that is being developed globally for the treatment of various cancers including triple-negative breast cancer, and fibrolamellar carcinoma. The company’s pipeline also includes three in-licensed oncology products, namely, Zevalin for non-Hodgkin’s lymphoma; Marqibo for acute lymphoblastic leukemia; and Evomela (melphalan) for multiple myeloma. The company operates subsidiaries in the US and China and a research and development center in Beijing, China. CASI is headquartered in Rockville, Maryland, the US.

Scope

Detailed information on CASI Pharmaceuticals Inc required for business and competitor intelligence needs

A study of the major internal and external factors affecting CASI Pharmaceuticals Inc in the form of a SWOT analysis

An in-depth view of the business model of CASI Pharmaceuticals Inc including a breakdown and examination of key business segments

News about CASI Pharmaceuticals Inc, such as business expansion, restructuring, and contract wins

Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

Gain understanding of CASI Pharmaceuticals Inc and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess CASI Pharmaceuticals Inc as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on CASI Pharmaceuticals Incs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Viva Biotech Ltd

Trovagene Inc

Shanghai GeneChem Co Ltd

Natsar Pharmaceuticals Inc

Hualan Biological Engineering Inc

Genentech Inc

Fennec Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

CASI Pharmaceuticals Inc - Key Facts

CASI Pharmaceuticals Inc - Key Employees

CASI Pharmaceuticals Inc - Key Employee Biographies

CASI Pharmaceuticals Inc - Major Products and Services

CASI Pharmaceuticals Inc - History

CASI Pharmaceuticals Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 Company Analysis

Company Overview

CASI Pharmaceuticals Inc - Business Description

CASI Pharmaceuticals Inc - Corporate Strategy

CASI Pharmaceuticals Inc - SWOT Analysis

SWOT Analysis - Overview

CASI Pharmaceuticals Inc - Strengths

CASI Pharmaceuticals Inc - Weaknesses

CASI Pharmaceuticals Inc - Opportunities

CASI Pharmaceuticals Inc - Threats

CASI Pharmaceuticals Inc - Key Competitors

Section 3 Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 Company’s Lifesciences Financial Deals and Alliances

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

CASI Pharmaceuticals Inc, Recent Deals Summary

Section 5 Company’s Recent Developments

Mar 29, 2019: CASI Pharmaceuticals announces fourth quarter and full year 2018 financial results and business results

Nov 16, 2018: CASI Pharmaceuticals to build GMP manufacturing site in Wuxi, China

Nov 14, 2018: CASI Pharmaceuticals announces third quarter and first nine months 2018 financial results

Oct 02, 2018: CASI Pharmaceuticals appoints Larry Zhang as president to its China operations to lead commercialization

Aug 14, 2018: CASI Pharmaceuticals announces second quarter and first half 2018 financial and business results

Jul 03, 2018: CASI Pharmaceuticals Added To Russell 2000, 3000 And Microcap Indexes

May 15, 2018: CASI Pharmaceuticals Announces First Quarter 2018 Financial And Business Results

Mar 29, 2018: CASI Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results

Section 6 Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List of Tables

List of Tables

CASI Pharmaceuticals Inc, Key Facts

CASI Pharmaceuticals Inc, Key Employees

CASI Pharmaceuticals Inc, Key Employee Biographies

CASI Pharmaceuticals Inc, Major Products and Services

CASI Pharmaceuticals Inc, History

CASI Pharmaceuticals Inc, Other Locations

CASI Pharmaceuticals Inc, Subsidiaries

CASI Pharmaceuticals Inc, Key Competitors

CASI Pharmaceuticals Inc, Ratios based on current share price

CASI Pharmaceuticals Inc, Annual Ratios

CASI Pharmaceuticals Inc, Annual Ratios (Cont…1)

CASI Pharmaceuticals Inc, Interim Ratios

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

CASI Pharmaceuticals Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

CASI Pharmaceuticals Inc, Performance Chart (2014 – 2018)

CASI Pharmaceuticals Inc, Ratio Charts

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports